|

Navigating Ipilimumab and Nivolumab Treatment for Mesothelioma: Insights from the United Kingdom

ByHolly Zink
Navigating Ipilimumab and Nivolumab Treatment for Mesothelioma: Insights from the United Kingdom

Being diagnosed with mesothelioma is tough. However, it’s vital to know about new treatments and their effects. In the United Kingdom, Ipilimumab and Nivolumab (IPI/NIVO) are now the top treatments.

A new article in Lung Cancer reviews Ipilimumab and Nivolumab results and factors, using a study from a UK hospital.

Understanding the Treatment Landscape

The arrival of IPI/NIVO has changed mesothelioma treatment. It comes from the CHECKMATE 743 study, which showed great results. This treatment improves survival more than standard chemotherapy. It’s especially good for patients with non-epithelioid mesothelioma. The side effects of IPI/NIVO are similar to those in other cancers.

A study at a UK center looked at mesothelioma patients on IPI/NIVO treatment. It aimed to check its real-world success and safety. The study covered 62 patients. Most had the epithelioid subtype (73%), while the rest had non-epithelioid (27%).

Overall, patients survived for 24.0 months on average. This was true for both subtypes. Survival rates were good. At one year, it was 78.89%, and at two, 52.1%. This shows the treatment’s long-term benefits.

About 45% of patients faced severe side effects. Colitis, or swelling and inflammation of the colon, was most common. Almost 40% needed high-dose steroids for these. This highlights the need for ongoing symptom management. For some patients, extra treatments were necessary (11%). However, survival wasn’t affected in these cases.

One interesting finding was that patients in later treatments fared as well as those in the first line. This shows IPI/NIVO’s potential in managing mesothelioma.

Key Takeaways for Patients and Caregivers

Staying updated on mesothelioma treatments is key for patients and caregivers. Knowing about IPI/NIVO therapy, its benefits, and side effects is crucial for making informed decisions. Managing side effects, like colitis, well is important for positive outcomes. Patients should quickly report symptoms to get the right care.

The timing of IPI/NIVO treatment, whether early or later, doesn’t affect survival much. Discussing options when it comes to timing with healthcare providers is vital. They can help choose the best treatment based on the patient’s situation.

Experience with Ipilimumab and Nivolumab at a UK center shows their value for mesothelioma. Being informed and working closely with healthcare providers gives patients and caregivers the confidence and hope to manage mesothelioma.

Source:

McMahon, David John, Trisha Patel, Rehab Ahmed, Alexius John, Elizabeth Cartwright, Thubeena Manickavasagar, Charlotte Milner-Watts, et al. “73 Ipilimumab and Nivolumab for Mesothelioma: A Real-World UK Tertiary Centre Experience.” Lung Cancer 190 (April 1, 2024). https://doi.org/10.1016/j.lungcan.2024.107634.

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…